BiotechTube

Vigabatrin + Matching Placebo

Phase 2/3Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cocaine Addiction

Conditions

Cocaine Addiction, Cocaine Dependence

Trial Timeline

Jan 1, 2011 → Dec 1, 2012

NCT ID
NCT01281202

About Vigabatrin + Matching Placebo

Vigabatrin + Matching Placebo is a phase 2/3 stage product being developed by Catalyst Pharmaceuticals for Cocaine Addiction. The current trial status is completed. This product is registered under clinical trial identifier NCT01281202. Target conditions include Cocaine Addiction, Cocaine Dependence.

What happened to similar drugs?

1 of 2 similar drugs in Cocaine Addiction were approved

Approved (1) Terminated (0) Active (1)
🔄Topiramate + Cognitive Behavioral Therapy + Placebo + Cognitive Behavioral TherapyJohnson & JohnsonPhase 3
✅quetiapineAstraZenecaApproved

Hype Score Breakdown

Clinical
15
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01281202Phase 2/3Completed

Competing Products

13 competing products in Cocaine Addiction

See all competitors
ProductCompanyStageHype Score
Topiramate + Cognitive Behavioral Therapy + Placebo + Cognitive Behavioral TherapyJohnson & JohnsonPhase 3
36
TopiramateJohnson & JohnsonPhase 2
35
quetiapineAstraZenecaApproved
43
quetiapine fumarate + Matched PlaceboAstraZenecaPre-clinical
26
AFQ056 + PlaceboNovartisPhase 1
21
AFQ056 + PlaceboNovartisPhase 2
35
ALKS 33-BUP + ALKS 33 + PlaceboAlkermesPhase 1
26
VIVITROL (Naltrexone extended-release injectable suspension) + PlaceboAlkermesPhase 2
32
vigabatrin + placeboCatalyst PharmaceuticalsPhase 2
29
Vigabatrin + PlaceboCatalyst PharmaceuticalsPhase 2
29
CPP-115 + PlaceboCatalyst PharmaceuticalsPhase 1
23
TNX-1300Tonix PharmaceuticalsPhase 2
17
TNX-1300 (Injection) + Placebo (Injection)Tonix PharmaceuticalsPhase 2
17